Spectacles and contact lenses represent the most widely available and accessible presbyopia correction options and are also (together with topical pharmacotherapy) the least invasive. Spectacles also ...

Broadly defined, there are currently three approaches to the management of presbyopia, each with its own advantages and disadvantages. External optical correction with spectacles or contact lenses is ...

The MarketWatch News Department was not involved in the creation of this content. The launch of emerging therapies, such as LNZ100 by Lenz Therapeutics, Phentolamine Ophthalmic Solution 0.75% by ...

LNZ100 shows superior efficacy and safety in presbyopia treatment, with a strong probability of FDA approval by August 2025. LNZ100 outperforms competitors Vuity and Qlosi, offering faster and greater ...

Presbyopia is defined as age-related loss of near vision that affects nearly everyone over age 45. The FDA has approved Vizz, an aceclidine ophthalmic solution 1.44%, making it the first and only ...

Struggling to read up close? Learn the signs of presbyopia and how eye care experts say you can manage this common ...

VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once ...

The FDA approved aceclidine 1.44% ophthalmic solution (Vizz) for adults with presbyopia, or age-related blurred near vision, maker Lenz Therapeutics announced on Thursday. It marks the first ...

Tenpoint Therapeutics Ltd and PHIL Partner to Launch YUVEZZI™ Direct-to-Patient Cash Program to Make Novel Presbyopia Therapy More Accessible and Affordable Tenpoint Therapeutics, a leading ophthalmic ...

A market for presbyopia eye drops that can sharpen vision with just one drop is expected to officially open in South Korea. Kwangdong Pharmaceutical announced on the 13th that its presbyopia treatment ...

Eye redness was not a commonly reported side effect in clinical trials of YUVEZZI. In BRIO I and BRIO II the reports of adverse events of ocular hyperemia (eye redness) were low. 1,2 In BRIO II, the ...